Atlas Trials

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Clinical trial NCT06936527 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT06936527
Sponsor
NovaOnco Therapeutics Co., Ltd.
Status
ENROLLING_BY_INVITATION
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Colorectal CancerMetastatic Colorectal Cancer With RAS Mutation
Start date
2025-05-23
Primary completion
2028-04-30
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.